Related Experiment Video
Updated: Jan 16, 2026
siRNA Electroporation to Modulate Autophagy in Herpes Simplex Virus Type 1-Infected Monocyte-Derived Dendritic Cells
Published on: October 28, 2019
Neutrophil membrane-camouflaged SiRNA nanoplatform targeting IL-33 attenuates osteoarthritis through
Zeze Fu1, Jiahao Chen1, Dengshuo Sun1
1Department of Orthopedics, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai Jiaotong University,, Shanghai, China.
Abstract:
Osteoarthritis (OA) imposes a substantial health and economic burden globally. Currently, there is a lack of disease-modifying osteoarthritis drugs (DMOADs). This study aimed to elucidate the relationship between chondrocyte senescence and OA progression, as well as to develop an effective siRNA nanodelivery platform for OA treatment. We engineered neutrophil membrane-coated, siIL33-loaded nanoparticles (NM-NP-siIL33) for OA management. The therapeutic efficacy of NM-NP-siIL33 was evaluated through both in vitro and in vivo experiments. Our findings revealed that IL-33 expression was significantly upregulated in damaged articular cartilage in both young and aged mice following anterior cruciate ligament transection (ACLT) surgery. In vitro experiments demonstrated that IL-33 promotes chondrocyte senescence by inhibiting cellular autophagy via activation of the p38 mitogen-activated protein kinase (MAPK) pathway. Additional in vivo studies showed that NM-NP-siIL33 effectively delivered siIL33 to target cells within OA tissues, thereby mitigating the degradation of articular cartilage. Our results suggest that IL-33 plays a critical role in OA progression by accelerating chondrocyte senescence. Furthermore, NM-NP-siIL33 represents a promising therapeutic strategy for managing OA.
Insights
Interleukin-33 (IL-33) accelerates osteoarthritis progression by promoting chondrocyte senescence. A novel nanoparticle delivery system (NM-NP-siIL33) effectively targets IL-33, showing promise for osteoarthritis treatment.
Area of Science:
- Biomedical Engineering
- Orthopedics
- Cell Biology
Background:
- Osteoarthritis (OA) is a degenerative joint disease with significant global health and economic impact.
- Current treatments for OA lack disease-modifying capabilities.
- Chondrocyte senescence is implicated in OA pathogenesis, but its precise role and therapeutic targets remain under investigation.
Purpose of the Study:
- To investigate the role of Interleukin-33 (IL-33) in chondrocyte senescence and OA progression.
- To develop and evaluate an siRNA nanodelivery platform for targeted OA therapy.
Main Methods:
- Engineered neutrophil membrane-coated nanoparticles loaded with siIL33 (NM-NP-siIL33).
- Evaluated IL-33 expression in mouse models of OA (ACLT surgery).
- Assessed the in vitro effects of IL-33 on chondrocyte senescence and autophagy via the p38 MAPK pathway.
- Determined the in vivo therapeutic efficacy of NM-NP-siIL33 in mitigating cartilage degradation.
Main Results:
- IL-33 expression was significantly upregulated in damaged articular cartilage post-ACLT.
- IL-33 was found to promote chondrocyte senescence by inhibiting autophagy through p38 MAPK pathway activation.
- NM-NP-siIL33 successfully delivered siIL33 to target cells in OA tissues.
- NM-NP-siIL33 treatment effectively reduced articular cartilage degradation in vivo.
Conclusions:
- IL-33 plays a critical role in OA pathogenesis by accelerating chondrocyte senescence.
- Targeting IL-33 with siRNA delivered via NM-NP-siIL33 is a promising therapeutic strategy for osteoarthritis.
